immunoglobulin
antibodi
ab
major
protein
compon
adapt
immun
system
direct
foreign
compound
infecti
agent
igg
molecul
consist
two
light
two
heavi
chain
connect
disulfid
bond
igg
monom
molecular
weight
kda
antigenbind
center
ab
form
hypervari
region
heavi
light
chain
classic
point
view
ab
molecul
contain
two
ident
antigenbind
site
two
hl
fragment
monospecif
bival
immunoglobulin
express
receptor
cell
membran
b
lymphocyt
well
form
solubl
molecul
secret
plasma
cell
solubl
ab
bind
virtual
natur
artifici
molecul
antigen
high
affin
specif
abil
ab
recogn
bind
broad
spectrum
antigen
ensur
extraordinari
divers
reach
differ
variant
antigenbind
center
bispecif
immunoglobulin
contain
two
differ
antigenbind
site
last
year
number
articl
devot
bispecif
ab
bsab
steadili
increas
particular
interest
molecul
due
potenti
therapeut
use
journal
natur
review
drug
discoveri
call
bsab
nextgener
antibodi
monoclon
ab
mab
secret
ident
immun
cell
clone
singl
parent
cell
mab
monospecif
bival
molecul
contrast
polyclon
ab
bind
epitop
antigen
fragment
recogn
ab
regard
mab
wide
use
treatment
cancer
avastin
bevacizumab
antivegf
herceptin
trastuzumab
antagonist
rituximab
pharmaceut
market
year
howev
drug
base
mab
abl
cure
case
cancer
monotherapi
particularli
due
lymphocyt
take
activ
part
destruct
tumor
mab
molecul
prevent
bind
growth
factor
receptor
mab
block
inhibitori
signal
protect
tumor
immun
cell
show
excel
result
treatment
particular
type
tumor
nevertheless
high
expect
focus
ab
bind
two
antigen
bsab
well
conjug
agent
chemo
bsab
develop
one
antigenbind
site
direct
receptor
activ
cytotox
lymphocyt
specif
antigen
tumor
cell
epitheli
cell
adhes
molecul
epcam
bcma
cea
other
converg
cytotox
lymphocyt
tumor
cell
due
bsab
bind
activ
cytotox
cell
promot
destruct
tumor
cell
addit
wide
rang
bsab
direct
tumor
sever
bispecif
molecul
treatment
diseas
develop
bsab
treatment
osteoporosi
block
factor
wnt
signaltransduct
pathway
sclerostin
enhanc
format
osteoblast
growth
bone
bind
bloodcoagul
factor
ix
x
design
reduc
bleed
rate
hemophilia
converg
coagul
factor
enhanc
coagul
bsab
transferrin
receptor
provid
passag
barrier
proteas
accumul
amyloid
peptid
candid
antialzheim
diseas
bsab
focus
autoimmun
diseas
usual
bind
cytokin
tnf
shown
simultan
use
two
mab
cytokin
autoimmun
diseas
sever
side
effect
without
superior
effici
regard
bsab
autoimmun
diseas
usual
combin
two
anticytokin
antigenbind
site
provid
higher
therapeut
potenti
mixtur
two
particular
therapeut
import
cytokin
psoriasi
clinic
effect
rheumatoid
arthriti
psoriat
contrast
phase
iii
clinic
trial
specif
preliminari
termin
due
safeti
antigenbind
site
direct
inflammatori
cytokin
found
cartilag
synovi
fluid
patient
bsab
sever
signific
advantag
monospecif
ab
bsab
direct
specif
effector
immun
system
target
tumor
cell
enhanc
cytotox
bsab
provid
higher
bind
specif
sinc
contrast
monospecif
ab
interact
two
differ
surfac
antigen
use
bsab
compar
combin
therapi
two
monospecif
drug
make
possibl
optim
expens
reduc
cost
develop
clinic
trial
sinc
one
diseas
modul
may
play
essenti
role
sever
independ
pathway
coexpress
differ
receptor
found
mani
tumor
target
two
differ
growthpromot
receptor
singl
tumor
cell
may
increas
antiprolif
effect
help
avoid
develop
sale
mab
present
pharmaceut
market
reach
us
billion
per
year
accord
estim
market
therapeut
bsab
grow
billion
per
year
therapeut
bsab
approv
medic
use
direct
treatment
liquid
tumor
blood
cancer
leukemia
lymphoma
specialti
liquid
tumor
palpabl
tumor
mechan
probe
form
bodi
unlik
solid
tumor
breast
uteru
rectum
leukemia
lymphoma
never
develop
symptom
typic
oncolog
patholog
sinc
malign
leukocyt
prolifer
bone
marrow
come
bloodstream
individu
cell
make
avail
bsab
therapi
diseas
bsab
develop
autoimmun
arthriti
asthma
diabet
infecti
pneumonia
hemophilia
alzheim
drug
blinatumomab
amgen
first
repres
bispecif
tcell
engag
bite
author
use
us
efficaci
blinatumomab
therapeut
drug
bcell
tumor
first
shown
patient
refractori
nonhodgkin
result
preclin
clinic
studi
publish
number
end
us
food
drug
administr
approv
treatment
blinatumomab
acut
lymphoblast
leukemia
without
philadelphia
chromosom
secondlin
eu
drug
regist
therapi
blinatumomab
lead
deplet
b
lymphocyt
precursor
peripher
blood
gradual
restor
end
bispecif
blinatumomab
molecul
develop
use
diabodi
technolog
first
antigenbind
site
direct
protein
surfac
b
lymphocyt
second
receptor
surfac
cytotox
lymphocyt
figur
singlestrand
structur
blinatumomab
allow
easi
protein
express
monomer
form
signific
amount
provid
broad
therapeut
potenti
use
lymphoma
unfortun
featur
reason
continu
intraven
administr
drug
requir
blinatumomab
molecul
direct
primari
cell
lymphoma
cell
provid
cytotox
low
concentr
pgml
direct
cytotox
lymphocyt
tumor
b
cell
bypass
tcell
receptor
major
histocompat
complex
signific
advantag
blinatumomab
increas
secret
antiinflammatori
cytokin
data
anim
model
also
confirm
high
efficaci
blinatumomab
tumor
cell
leukemia
lymphoma
low
blinatumomab
therapi
adult
patient
recurr
acut
lymphoblast
leukemia
lead
entir
posit
result
achiev
minim
residu
diseas
tumor
cell
remain
organ
remiss
averag
life
expect
therapi
therapi
nonhodgkin
lymphoma
blinatumomab
also
show
good
efficaci
monotherapi
clinic
trial
blinatumomab
significantli
exceed
effect
mab
therapi
muchlow
final
blood
treatment
nonhodgkin
lymphoma
patient
blinatumomab
result
minim
residu
diseas
even
induct
clinic
trial
still
way
refractori
recurr
acut
lymphoblast
leukemia
case
absenc
lymphocyt
surfac
extramedullari
hematopoiesi
format
lymphocyt
outsid
bone
marrow
therapi
blinatumomab
initi
blinatumomab
administr
number
b
lymphocyt
decreas
one
day
remain
virtual
undetect
end
therapi
contrari
number
lymphocyt
lower
patient
minimum
level
day
restor
normal
within
day
moreov
within
week
number
cell
doubl
patient
domin
expans
memori
cell
express
explain
differ
signal
pathway
use
memori
cell
rapid
remov
blinatumomab
bloodstream
due
low
molecular
weight
necess
regular
intraven
administr
partial
resolv
newer
therapeut
tetraval
ab
develop
administ
twice
week
lymphocyt
chimer
receptor
cart
provid
complet
remiss
patient
refractori
acut
lymphoblast
leukemia
vivo
cell
prolifer
howev
case
cart
therapi
incid
lymphocytereleas
syndrom
much
higher
case
blinatumomab
ab
antigen
eg
develop
use
bite
technolog
direct
treatment
myeloid
leukemia
lymphoma
current
undergo
clinic
catumaxomab
removab
trion
first
bispecif
trifunct
drug
approv
european
medicin
agenc
treatment
malign
catumaxomab
redirect
cell
tumor
cell
express
epcam
ascit
secondari
epitheli
form
cancer
especi
gastric
cancer
result
clinic
preclin
studi
catumaxomab
describ
detail
mani
catumaxomab
produc
use
quadroma
technolog
hl
fragment
mous
mab
rat
mab
epcam
secret
correspond
hybridoma
combin
one
bispecif
molecul
also
bind
fc
catumaxomab
preferenti
bind
activ
receptor
inhibitori
receptor
determin
recruit
activ
macrophag
nk
cell
dendrit
cell
lead
complex
use
hl
fragment
obtain
differ
host
organ
reduc
possibl
bsab
format
mismatch
light
chain
sinc
light
chain
rat
ab
predominantli
interact
rat
heavi
chain
vice
versa
light
chain
mous
ab
prefer
associ
heavi
mous
applic
catumaxomab
clinic
trial
therapi
prove
success
sinc
barrier
lymphocyt
catumaxomab
molecul
penetr
ascit
tumor
ascit
tumor
repres
separ
cell
float
separ
one
anoth
liquid
unit
lymphoma
leukemia
two
liquid
tumor
direct
blinatumomab
case
blinatumomab
antitumor
effect
catumaxomab
due
coloc
tlymphocyt
tumor
cell
express
epcam
cell
fc
receptor
surfac
macrophag
dendrit
cell
natur
killer
figur
therefor
catumaxomab
enhanc
activ
patient
immun
system
tumor
bind
catumaxomab
receptor
antigenpres
cell
turn
inflammatori
monocyt
express
costimulatori
molecul
necessari
tcell
preclin
studi
shown
catumaxomab
could
provid
immunorespons
due
b
tmemori
cell
activ
fc
phase
iiib
clinic
trial
intraperiton
infus
catumaxomab
favor
accumul
activ
macrophag
nk
cell
tcell
ascit
periton
interact
patient
immun
cell
tumor
cell
lead
complic
reaction
result
elimin
tumor
cell
studi
shown
sever
mechan
cytotox
lymphocytemedi
lysi
cytokin
action
chemokin
phagocytosi
abdepend
cellular
toxic
compar
bsab
individu
mous
rat
mab
antiepcam
show
significantli
lower
antitumor
catumaxomab
high
therapeut
potenti
accept
safeti
intraperiton
administr
low
dose
mg
drug
carri
four
five
time
interv
day
catumaxomab
approv
treatment
malign
ascit
current
undergo
clinic
trial
ovarian
stomach
epitheli
cancer
time
similar
therapeut
effect
observ
tumor
eg
ovarian
carcinoma
catumaxomab
reduc
format
ascit
interestingli
one
catumaxomabtherapi
side
effect
format
ab
mous
rat
ab
notabl
immunorespons
mous
ab
correl
posit
respons
antitumor
bsab
current
undergo
clinic
preclin
trial
blinatumomab
catumaxomab
contain
one
antigenbind
site
attract
lymphocyt
tumor
cell
second
antigenbind
site
direct
cea
disialogangliosid
psma
protein
tabl
also
mani
bsab
combin
antigenbind
site
usual
anticytokin
trial
data
bsab
undergo
clinic
trial
publish
mani
review
combin
tabl
list
termin
clinic
trial
combin
tabl
structur
common
bsab
format
present
figur
like
method
therapi
sever
diseas
therapeut
bsab
caus
differ
side
effect
common
nausea
vomit
abdomin
pain
fatigu
leukopenia
neutropenia
thrombopenia
mani
patient
ab
therapeut
bsab
appear
blood
treatment
advers
event
occur
begin
therapi
case
side
effect
normal
continu
treatment
major
data
therapeut
bsab
advers
effect
avail
blinatumomab
catumaxomab
sinc
drug
undergon
numer
clinic
trial
common
side
effect
blinatumomab
catumaxomab
therapi
cytokin
storm
elev
cytokin
level
cytokin
releaserel
symptom
gener
side
effect
mani
therapeut
mab
occur
due
specif
mechan
action
use
cytotox
cell
effector
minim
cytokinereleas
syndrom
possibl
low
initi
dose
drug
combin
subsequ
high
well
corticosteroid
dexamethason
premed
common
side
effect
blinatumomab
treatment
hepatotox
leukopenia
lymphopenia
thrombocytopenia
crp
increas
chill
fever
pyrexia
nausea
also
note
neurolog
psychiatr
side
effect
complet
revers
end
catumaxomab
treatment
frequent
advers
event
cytokin
releaserel
symptom
may
predict
valu
treatment
efficaci
disord
liver
paramet
white
blood
cell
often
observ
usual
chang
advers
event
case
bite
bsab
antiepcam
gener
due
activ
cell
treatment
bite
bsab
anticea
common
side
effect
nausea
vomit
abdomin
pain
fatigu
signific
increas
antidrug
ab
detect
blood
half
main
advers
event
anticea
fab
fab
therapi
bonemarrow
bsab
gener
attach
light
heavi
chain
singledomain
ab
singlechain
variabl
fragment
scfv
genet
engin
structur
addit
antigenbind
site
amino
carboxyl
end
monospecif
igg
wide
format
use
igg
dualvari
domain
dvdig
variabl
part
hl
fragment
ad
anoth
variabl
part
anoth
ab
short
peptid
linker
result
molecul
bispecif
bival
regard
exampl
tetraval
tetraspecif
ab
bind
egfr
vegf
construct
combin
dvdig
technolog
one
advantag
bsab
design
dvdig
technolog
abil
simultan
bind
antigen
variabl
domain
especi
true
case
bind
cytokin
protein
present
blood
low
concentr
also
allow
less
frequent
administr
chemic
conjug
bsab
gener
use
first
time
two
obtain
pepsinolysi
rabbit
igg
reduc
oxid
result
bispecif
subsequ
homo
heterobifunct
reagent
interact
cystein
fab
obtain
genet
use
covxbodi
technolog
modern
approach
prepar
bsab
base
sitespecif
attach
lowmolecularweight
ligand
halflif
lowmolecularweight
drug
increas
significantli
attach
hl
fragment
bsab
produc
addit
two
short
peptid
inhibit
vegf
angiopoietin
branch
linker
howev
clinic
trial
termin
ahead
schedul
due
lack
pharmacolog
chemic
conjug
ab
rituximab
use
obtain
cell
bsabcoat
autolog
polyclon
activ
lymphocyt
gener
surfac
local
antigenbind
site
receptor
cell
first
phase
clinic
trial
administ
highdos
chemotherapi
transplant
peripher
blood
stem
cell
inject
increas
natur
specif
cellular
respons
refractori
nonhodgkin
develop
immtac
technolog
contain
singlechain
mab
attach
matur
tcell
receptor
recogn
peptid
human
leukocyt
antigen
drug
undergo
clinic
trial
metastat
direct
activ
effector
cell
memori
death
melanoma
cell
antigen
present
dendrit
dockandlock
method
allow
product
polyval
multispecif
multifunct
linker
coval
bond
first
fab
dimer
dock
domain
campdepend
protein
kinas
contain
sulfhydryl
group
second
fab
bond
anchor
domain
akinas
contain
two
sulfhydryl
group
interact
two
campdepend
proteinkinas
domain
result
dimer
structur
carri
fab
result
fragment
bind
protein
akinas
domain
bear
third
fab
format
disulfid
bond
coval
stabil
tripl
trifunct
construct
contain
four
cytokin
molecul
link
ab
veltuzumab
effect
nonhodgkin
lymphoma
multipl
hexaval
construct
contain
bsab
veltuzumab
epratuzumab
penetr
lipid
raft
stimul
apoptosi
inhibit
tumor
hexaval
construct
compos
bsab
epratuzumab
enhanc
format
immunolog
synaps
trogocytosi
transmiss
antigen
b
lymphocyt
antigenpres
cell
repres
candid
molecul
treatment
autoimmun
anoth
construct
contain
singlechain
ab
coval
bound
antitumor
fab
dimer
bispecif
bind
bsab
tumor
cell
cell
result
antitumor
tcell
therapeut
ab
fragment
scfv
diabodi
may
fuse
protein
bind
increas
halflif
drug
blood
five
six
time
construct
molecul
give
unpredict
result
therebi
bsab
gener
result
differ
abfrag
fusion
bind
ab
protein
limit
applic
research
develop
new
therapeut
molecul
format
bsab
gener
base
ab
abfrag
conjug
today
use
possibl
stabl
fusion
recombin
protein
coexpress
two
heavi
two
lightchain
gene
one
cell
may
result
express
igglik
molecul
method
allow
creation
prepar
monoclon
bispecif
ab
catumaxomab
quadroma
technolog
impli
fusion
two
cell
line
produc
ab
gener
hybrid
hybridoma
cell
heavi
light
chain
two
differ
ab
combin
result
bsab
convent
igglik
structur
retain
effector
function
mediat
fc
case
quadroma
bsab
constant
region
heavi
light
chain
differ
isotyp
even
differ
speci
triomab
sever
variant
quadromaproduc
cell
select
describ
first
method
use
two
cell
line
produc
mab
resist
differ
antibiot
case
hybrid
cell
carri
resist
marker
antibiot
one
advantag
method
function
stabil
fuse
nuclei
cell
hybrid
anoth
method
use
fluorescenceactiv
cell
sort
one
hybridoma
cell
line
modifi
fluorescein
isothiocyan
anoth
tetramethyl
rhodamin
fusion
hybrid
cell
carri
two
fluoresc
marker
select
electrofus
techniqu
innocu
altern
polyethylen
glycol
fusion
also
main
problem
twoab
coexpress
particularli
quadroma
format
nine
variant
undesir
chimer
ab
along
target
bsab
problem
origin
due
homodimer
heavi
chain
instead
heterodimer
random
bind
light
chain
heavi
chain
result
signific
disadvantag
method
low
yield
target
yield
heterodim
two
differ
heavi
chain
increas
use
knobinhol
method
one
heavi
chain
mutat
knob
replac
steric
bulki
amino
acid
join
second
heavi
chain
mutat
hole
replac
smaller
amino
acid
format
heterodim
thermodynam
variant
method
use
structur
similar
igg
iga
domain
ensur
format
heterodim
heavi
sever
method
bsab
product
use
one
type
light
howev
wide
use
method
bsab
product
today
express
monospecif
mab
two
differ
cell
line
isol
subsequ
combin
advantag
approach
use
wellcharacter
ab
signific
disadvantag
high
cost
difficulti
obtain
bsab
contain
paratop
recogn
two
differ
antigen
demonstr
ab
bind
ab
bind
crossmab
technolog
develop
roch
made
possibl
gener
tetraspecif
ab
bind
egfr
dutamab
technolog
creativ
biolab
roch
use
three
complementaritydetermin
region
cdr
antigenbind
site
bind
one
three
cdr
bind
second
antigen
thu
form
two
paratop
technolog
allow
bsab
produc
use
method
typic
monospecif
ab
drawback
approach
nonunivers
possibl
pair
antigen
match
paratop
within
singl
antigenbind
bsab
contain
constant
region
describ
popular
demand
format
diabodi
bite
bsab
express
one
cell
fragment
heavi
light
chain
connect
short
peptid
sequenc
scfv
wide
use
gener
bsab
diabodi
gener
sequenc
encod
two
differ
scfv
combin
one
construct
heavi
chain
express
singl
polypeptid
join
correspond
light
chain
first
describ
diabodi
bival
heterodimer
construct
later
obtain
knobinhol
singlechain
diabodi
diabodi
technolog
use
construct
first
bite
eukaryot
cell
bite
small
scfv
molecul
tandem
connect
flexibl
peptid
linker
bite
usual
contain
antigenbind
site
anoth
highaffin
surfac
antigen
tumor
disadvantag
molecul
short
life
span
blood
serum
associ
small
lack
fc
advantag
bsab
format
extrem
highli
specif
antitumor
activ
concentr
pgml
cell
accord
data
one
bite
molecul
involv
sever
time
elimin
tumor
cell
cytotox
singledomain
ab
fragment
obtain
mous
human
librari
phage
display
also
use
construct
nanobodi
deriv
llama
camel
contain
heavi
chain
product
bsab
nanobodi
readili
connect
short
peptid
advantag
use
singledomain
ab
fragment
small
easi
penetr
cell
access
antigen
hidden
igg
signific
disadvantag
small
structur
low
halflif
blood
requir
frequent
inject
success
repres
bite
famili
blinatumomab
amgen
also
develop
bite
bind
epcam
cea
mcsp
current
undergo
clinic
combin
two
vl
vh
domain
one
polypeptid
make
possibl
obtain
tetraval
tandab
molecul
tandab
combin
antigenbind
site
enhanc
respons
natur
killer
hodgkin
lymphoma
two
antigenbind
site
antigen
lack
fc
increas
molecular
weight
vivo
stabil
blinatumomab
catumaxomab
approv
use
medicin
design
treat
oncolog
diseas
perspect
one
expect
construct
new
platform
allow
develop
full
process
bsab
express
preclin
test
develop
new
antitumor
drug
necessari
search
new
combin
bsab
target
increas
therapeut
effect
reduc
side
effect
specif
featur
tumor
also
taken
account
bsab
use
combin
medic
eg
drug
control
cell
cycl
indoleamin
dioxygenas
inhibitor
vaccin
doubt
continu
develop
new
approach
bsab
product
requir
control
oncolog
diseas
design
new
bsab
like
includ
abil
bind
two
tumor
antigen
combin
attract
lymphocyt
assist
cell
immunosynaps
particular
import
increas
bsab
specif
sensit
well
reduc
cytotox
nontumor
cell
import
task
increas
bsab
yield
hybridoma
decreas
cost
drug
promis
work
short
nonvir
minicircl
dna
synthesi
bsab
vivo
recent
publish
bsab
effici
stimul
tcell
cytotox
lymphoma
cell
line
introduct
plasmid
dna
suffici
month
bsab
express
oncolyt
adenoviru
express
bispecif
singlechain
ab
tumor
cell
construct
secret
ab
format
bite
bsab
bind
epcam
tumor
cell
activ
tcell
cytotox
direct
rel
univers
method
bsab
prepar
exchang
igg
hl
fragment
occur
stochast
natur
mutat
disulfid
accord
literatur
hlfragment
exchang
occur
human
blood
milk
placenta
igg
subclass
result
polyreact
howev
exchang
hl
fragment
therapeut
molecul
bispecif
patient
lead
format
bsab
possess
origin
impos
signific
limit
method
short
time
one
may
expect
complet
clinic
trial
approv
bsab
direct
treat
autoimmun
diseas
exampl
promis
result
obtain
antihiv
bsab
shown
bsab
direct
site
env
protein
exhibit
synergist
effect
vivo
vitro
variant
antihiv
bsab
combin
antigenbind
site
protein
use
prevent
hiv
design
bispecif
molecul
demand
analysi
requir
bsab
properti
affin
target
molecul
pharmacokinet
blood
near
target
cell
mechan
action
increas
number
therapeut
bsab
enter
clinic
trial
result
bsab
use
clinic
medicin
may
improv
understand
pharmacokinet
near
futur
ideal
therapeut
bsab
expect
long
halflif
human
blood
distribut
among
organ
suffici
penetr
use
bsab
diagnost
tool
promis
sinc
bsab
simplifi
detect
target
antigen
bsab
use
sensit
immunoassay
develop
simpl
rapid
detect
bacteri
viral
infecti
diseas
cancer
bsab
significantli
enhanc
qualiti
reliabl
vivo
cancerdiagnost
imag
positronemiss
tomographi
use
bsab
hapten
allow
pretarget
human
prostat
cancer
xenograft
sever
combin
immunodefici
mice
minim
signal
background
high
sensit
specif
use
bsab
method
superior
lipoarabinomannan
present
blood
tuberculosi
patient
consid
diseas
marker
bsab
specif
lipoarabinomannan
horseradish
peroxidas
develop
quadroma
technolog
use
immunoswab
shown
specif
sensit
compar
bacteri
cultur
result
obtain
within
hour
sampl
collect
competit
compar
standard
laboratorycultur
method
result
obtain
week
use
antihbsag
antihuman
erythrocyt
bsab
allow
detect
hepat
b
specif
sensit
method
use
activ
infect
patient
sinc
serum
hbsag
detect
level
rang
ngml
quadroma
express
bsab
escherichia
coli
lipopolysaccharid
whole
bacteria
combin
horseradish
peroxidas
use
rapid
onestep
sandwich
enzymelink
immunosorbentassay
detect
e
coli
strain
sensit
detect
cfuml
specif
sinc
detect
salmonella
pseudomona
nonpathogen
e
approach
use
bordetella
pertussi
detect
quadroma
produc
antib
pertussi
lipopolysaccharid
antihorseradish
peroxidas
bsab
construct
ultrasensit
similar
method
develop
bsab
detect
staphylococcu
aureu
assay
highli
sensit
specif
due
releas
bound
fluoresc
report
bsabact
center
bind
thermonucleasespecif
antigen
bsab
recogn
sever
epitop
np
antigen
sar
coronaviru
caus
sever
acut
respiratori
syndrom
bind
horseradish
peroxidas
use
immunoswab
assay
sensit
np
detect
pgml
high
develop
new
method
bsab
gener
made
possibl
obtain
variou
variant
promis
ab
deriv
use
therapi
result
bsab
differ
natur
igg
pharmacokinet
blood
serum
halflif
abil
penetr
tumor
size
valenc
presenc
fc
simultan
block
sever
biolog
pathway
allow
bsab
exhibit
synergist
effect
unachiev
mixtur
monospecif
ab
result
recent
year
indic
close
futur
combin
method
develop
earlier
new
bsab
direct
varieti
diseas
simultan
bind
sever
specif
antigen
play
key
role
gener
bsab
may
use
develop
diagnost
devic
next
gener
potenti
simultan
detect
sever
antigen
combin
antigenbind
site
assay
marker
make
bsab
import
object
research
biomedicin
pharmacolog
diagnost
